Literature DB >> 32107339

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.

Rakesh Popat1, Dana Warcel2, Jenny O'Nions2, Anna Cowley2, Sasha Smith2, William R Tucker3, Kwee Yong2, Simona Degli Esposti3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32107339      PMCID： PMC7193475          DOI： 10.3324/haematol.2019.235937

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics.

Authors:  Tanja Guthoff; Bettina Tietze; Berit Meinhardt; Jan Becher; Rainer Guthoff
Journal:  Ophthalmologica       Date:  2010-03-23       Impact factor: 3.250

2.  Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Authors:  Nizar M Tannir; Andres Forero-Torres; Radhakrishnan Ramchandren; Sumanta K Pal; Stephen M Ansell; Jeffrey R Infante; Sven de Vos; Paul A Hamlin; Stella K Kim; Nancy C Whiting; Elaina M Gartner; Baiteng Zhao; John A Thompson
Journal:  Invest New Drugs       Date:  2014-08-22       Impact factor: 3.850

3.  Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Authors:  Sagar Lonial; Hans C Lee; Ashraf Badros; Suzanne Trudel; Ajay K Nooka; Ajai Chari; Al-Ola Abdallah; Natalie Callander; Nikoletta Lendvai; Douglas Sborov; Attaya Suvannasankha; Katja Weisel; Lionel Karlin; Edward Libby; Bertrand Arnulf; Thierry Facon; Cyrille Hulin; K Martin Kortüm; Paula Rodríguez-Otero; Saad Z Usmani; Parameswaran Hari; Rachid Baz; Hang Quach; Philippe Moreau; Peter M Voorhees; Ira Gupta; Axel Hoos; Eric Zhi; January Baron; Trisha Piontek; Eric Lewis; Roxanne C Jewell; Elisha J Dettman; Rakesh Popat; Simona Degli Esposti; Joanna Opalinska; Paul Richardson; Adam D Cohen
Journal:  Lancet Oncol       Date:  2019-12-16       Impact factor: 41.316

4.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

Review 5.  Multiple myeloma.

Authors:  Shaji K Kumar; Vincent Rajkumar; Robert A Kyle; Mark van Duin; Pieter Sonneveld; María-Victoria Mateos; Francesca Gay; Kenneth C Anderson
Journal:  Nat Rev Dis Primers       Date:  2017-07-20       Impact factor: 52.329

6.  Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates.

Authors:  Hui Zhao; John Atkinson; Sara Gulesserian; Zhilan Zeng; Jenny Nater; Jimmy Ou; Peng Yang; Karen Morrison; Jeffrey Coleman; Faisal Malik; Pia Challita-Eid; Sher Karki; Hector Aviña; René Hubert; Linnette Capo; Josh Snyder; Sung-Ju Moon; Roland Luethy; Brian A Mendelsohn; David R Stover; Fernando Doñate
Journal:  Cancer Res       Date:  2018-01-30       Impact factor: 12.701

Review 7.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Authors:  R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

Review 8.  Update in Current Diagnostics and Therapeutics of Dry Eye Disease.

Authors:  Praneetha Thulasi; Ali Reza Djalilian
Journal:  Ophthalmology       Date:  2017-11       Impact factor: 12.079

Review 9.  Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.

Authors:  Heather Donaghy
Journal:  MAbs       Date:  2016-04-05       Impact factor: 5.857

Review 10.  Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Authors:  Shih-Feng Cho; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561
View more
  10 in total

1.  Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates.

Authors:  Julia Canestraro; Malin Hultcrantz; Shanu Modi; Paul A Hamlin; Alexander N Shoushtari; Jason A Konner; William P Tew; Neil M Iyengar; Murk Heinemann; David H Abramson; Jasmine H Francis
Journal:  Cornea       Date:  2021-11-23       Impact factor: 3.152

Review 2.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

Review 3.  Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.

Authors:  Massimo Offidani; Laura Corvatta; Sonia Morè; Attilio Olivieri
Journal:  Drug Des Devel Ther       Date:  2021-06-02       Impact factor: 4.162

Review 4.  Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.

Authors:  Alessandra Romano; Paola Storti; Valentina Marchica; Grazia Scandura; Laura Notarfranchi; Luisa Craviotto; Francesco Di Raimondo; Nicola Giuliani
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

5.  [New treatments present new challenges : Ocular side effects of belantamab mafodotin].

Authors:  Peter Werkl; Nora Woltsche; Barbara Silbernagel; Gernot Schließleder; Wolfgang List; Gernot Steinwender; Ingrid Boldin; Jutta Horwath-Winter
Journal:  Ophthalmologie       Date:  2021-05-12

6.  Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.

Authors:  Asim V Farooq; Simona Degli Esposti; Rakesh Popat; Praneetha Thulasi; Sagar Lonial; Ajay K Nooka; Andrzej Jakubowiak; Douglas Sborov; Brian E Zaugg; Ashraf Z Badros; Bennie H Jeng; Natalie S Callander; Joanna Opalinska; January Baron; Trisha Piontek; Julie Byrne; Ira Gupta; Kathryn Colby
Journal:  Ophthalmol Ther       Date:  2020-07-25

Review 7.  The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.

Authors:  Melody R Becnel; Hans C Lee
Journal:  Ther Adv Hematol       Date:  2020-12-14

Review 8.  Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.

Authors:  Grace Lassiter; Cole Bergeron; Ryan Guedry; Julia Cucarola; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Curr Oncol       Date:  2021-01-21       Impact factor: 3.677

9.  Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).

Authors:  Sagar Lonial; Ajay K Nooka; Praneetha Thulasi; Ashraf Z Badros; Bennie H Jeng; Natalie S Callander; Heather A Potter; Douglas Sborov; Brian E Zaugg; Rakesh Popat; Simona Degli Esposti; Julie Byrne; Joanna Opalinska; January Baron; Trisha Piontek; Ira Gupta; Reza Dana; Asim V Farooq; Kathryn Colby; Andrzej Jakubowiak
Journal:  Blood Cancer J       Date:  2021-05-26       Impact factor: 11.037

Review 10.  Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.

Authors:  Waqqas Tai; Ahsan Wahab; Diana Franco; Zunairah Shah; Aqsa Ashraf; Qurrat-Ul-Ain Abid; Yaqub Nadeem Mohammed; Darshan Lal; Faiz Anwer
Journal:  Antibodies (Basel)       Date:  2022-03-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.